Related Experiment Videos
Iron dextran treatment in peritoneal dialysis patients on erythropoietin
1Dept. of Medicine, State University of New York, Stony Brook.
Study Objective:
To evaluate maintenance parenteral iron dextran in chronic peritoneal dialysis (PD) patients receiving erythropoietin (rHuEPO).
Design:
Parenteral iron dextran was investigated in PD patients with poor response to rHuEPO and/or side effects of oral iron.
Setting:
Tertiary-referral university hospital
Patients And Methods:
Seven ESRD patients (five males and two females) were studied. A test dose of 25 mg iron dextran was given before starting a maintenance dose. Iron dextran 100 mg was given intramuscular weekly or biweekly. Six patients received rHuEPO and one patient was on decadurabolin.
Results:
Hematocrits increased significantly (p < 0.01) from 29 +/- 2% to 38 +/- 2% and serum ferritin increased from 267 +/- 104 to 660 +/- 104 ng/dl after iron dextran. Serum albumin increased from 3.1 +/- 0.3 to 3.6 +/- 0.2 g/dl (p < 0.05). No patient developed an anaphylactic reaction or delayed reaction. Mean duration of parenteral iron dextran treatment was 7 +/- 1 months. Mean dose of erythropoietin was reduced significantly (p < 0.05) from 119 +/- 20 units/kg/week to 87 +/- 20 units/kg/week before and during fifth month of iron dextran therapy.
Conclusions:
Weekly/biweekly maintenance intramuscular iron dextran injection was effective and safe iron supplemental therapy in PD patients with poor response or side effects to oral iron.